DOCSLIB.ORG

Zurich, Switzerland

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Zurich, Switzerland HIRSLANDEN INVESTOR DAY PRESENTATION 18 FEBRUARY 2015 WELCOME & INTRODUCTION DANIE MEINTJES CEO MEDICLINIC INTERNATIONAL TIME LINE AND FINANCIAL OVERVIEW CRAIG TINGLE CFO MEDICLINIC INTERNATIONAL HIRSLANDEN TIME LINE 1990 2005 Merger of 5 clinics to form 1997 – 2002 2002 Takeover of Klinik St. Anna HIRSLANDEN Takeover of 7 clinics Takeover by BC Partners Introduction of Tarmed 2007 2010 2007 2007 Mediclinic International Acquisition of Klinik New management team at Opening of Garden Wing at acquires Hirslanden’s 13 Stephanshorn Hirslanden Klinik Hirslanden hospitals 2013 2012 2012 2012 Enzenbühltrakt project Successful listing of 13 Major debt refinancing of completed at Klinik KVG revision and hospitals on cantonal CHF2.9 billion successfully Hirslanden introduction of DRGs hospital lists completed Opening of outpatient clinic at Bern Station 2014 2014 2015 2014 ABO funding Commissioning of First bond issues totalling Opening of outpatient Acquisition of Clinique La Männedorf radiotherapy CHF200 million clinic in Belair “Urbahn” Colline and Swissana unit Clinic Hirslanden Analyst Presentation | February 2015 5 HIRSLANDEN KEY FINANCIAL INDICATORS Revenue and EBITDA CAGR = 6.2% 1 500 CAGR = 5.1% 1 200 900 CHF‘m 600 CHF 299 CHF 286 CHF 285 CHF 278 CHF 266 CHF 245 300 CHF 222 CHF 1 001 CHF 1 091 CHF 1 134 CHF 1 218 CHF 1 270 CHF 1 330 CHF 1 436 0 FY2008 FY2009 FY2010 FY2011 FY2012 FY2013 FY2014 Revenue EBITDA • Steady revenue and EBITDA growth • Normalised EBITDA shown • Major structural changes since early 2012 with listing, increase in generally insured patients and major long-term projects such as Lighthouse Hirslanden Analyst Presentation | February 2015 6 HIRSLANDEN GEARING Net debt : EBITDA 2,5 12,0 10,6 9,5 2,0 10,0 8,8 8,2 8,5 1,5 8,0 CHF’bn) 6,7 6,1 1,0 6,0 Net debt ( 0,5 4,0 CHF 2,34 CHF 2,34 CHF 2,33 CHF 2,34 CHF 2,37 CHF 1,91 CHF 1,83 0,0 2,0 FY2008 FY2009 FY2010 FY2011 FY2012 FY2013 FY2014 Net debt Net debt: EBITDA • Declining net debt to EBITDA ratio • Positive effect of debt refinancing in October 2012 clearly seen from FY2013 onward • After refinancing, average interest rate decreased from 5.62% to 2.3% • CHF 180 m amortised on senior loan as at 30 September 2014 Hirslanden Analyst Presentation | February 2015 7 HIRSLANDEN INAUGURAL DUAL TRANCHE BOND ISSUE • On 29 January 2015 Hirslanden accessed the CHF bond market • CHF 120 million at 1.625 % over 6 years, in combination with a CHF 80 million at 2.00 % with 10 year maturity • Final closing next week and further volume is possible • Aim of offering to refinance existing debt and diversify funding sources • Currently further refinancing options being evaluated • Rating of Baa- stable by Fedafin and Mid BB stable by Credit Suisse • Total transaction size the largest CHF new issue volume by a domestic health care sector issuer Hirslanden Analyst Presentation | February 2015 8 OPERATIONAL OVERVIEW OLE WIESINGER CEO HIRSLANDEN KEY FACTS SWITZERLAND Hirslanden Analyst Presentation | February 2015 10 KEY FACTS SWITZERLAND Official languages: Capital: Area: Government: German None 41,285 km² Federal Multi- French party directorial 133rd Italian (Berne) republic Romansh Population: GDP (PPP): Human GDP development (per capita): 8 million $ 385.333 index (HDI): Billion 0.917 $ 47,863 37th 3rd 8th Hirslanden Analyst Presentation | February 2015 11 KEY FACTS LIFE EXPECTANCY AT BIRTH 1970 AND 2011 (OR NEAREST YEAR) 90 80 70 60 50 40 30 20 10 0 Switzerland Germany OECD USA UAE India South Africa Data: OECD Health Statistics 2013. | Source UAE: indexmundi. United Arab Emirates - Life expectancy at birth Hirslanden Analyst Presentation | February 2015 12 KEY FACTS HEALTH EXPENDITURE PER CAPITA IN USD, 2011 (OR NEAREST YEAR) 9000 8000 7000 6000 5000 4000 3000 2000 1000 0 Switzerland Germany OECD USA UAE India South Africa Data: OECD Health Statistics 2013. | Source UAE: The World Bank - Health expenditure per capita Hirslanden Analyst Presentation | February 2015 13 ENVIRONMENTAL CHALLENGES Hirslanden Analyst Presentation | February 2015 14 ENVIRONMENTAL CHALLENGES Outmigration of care Decreasing turnover per case Aging society From acute to chronical Regulatory environment Human resources Power of networks Increased transparency Limited market access Hirslanden Analyst Presentation | February 2015 15 REGULATORY ENVIRONMENT SWISS POLITICAL SYSTEM • Multi-party federal directorial democratic republic • Federal Council of Switzerland as head of government and executive power • Legislative power exercised by government and two chambers: Council of State and National Council • Direct representation • Healthcare: Steered by cantonal governments Hirslanden Analyst Presentation | February 2015 16 REGULATORY ENVIRONMENT SWISS FEDERAL STRUCTURE Hirslanden Analyst Presentation | February 2015 17 REGULATORY ENVIRONMENT THE CANTONS’ MULTIPLES ROLES Finance HSM Moratorium planning payer Tariff Healthcare Hospital determina- regulator operator tion Hirslanden Analyst Presentation | February 2015 18 HSM PLANNING THE APPROACH «Conference of Highly Specialized Medicine» (assigned by the 26 Health Ministers), organised by cantons Purpose: Centralisation of Highly Specialized Medicine in Switzerland Motivation criteria: • Small case load • Innovation potential • Need for specialized teams • Need for specialized infrastructures • Complexity of treatments • High costs Hirslanden Analyst Presentation | February 2015 19 HSM PLANNING THE CHALLENGE • Definition of HSM: What and who? • Distinction between specialised and highly-specialised medicine • Composition of decision making-body: Only representatives of public hospitals with multiple roles Hirslanden Analyst Presentation | February 2015 20 REGULATORY ENVIRONMENT THE CANTONS’ MULTIPLES ROLES Finance HSM Moratorium planning payer Tariff Healthcare Hospital determina- regulator operator tion Hirslanden Analyst Presentation | February 2015 21 HEALTHCARE REGULATOR HOSPITAL LIST - THE APPROACH • Cantonal hospital lists • Goal of list: Cover all medical services required by the inhabitants of canton • Billing of treatment costs to patient’s canton of residence and basic insurance (50:50) by listed hospitals • Listing made by cantonal government • Mandate dictates offered medical services, obligations and requirements to be met (most important: Quality and economic efficiency, patients access to treatment, within a reasonable time) Hirslanden Analyst Presentation | February 2015 22 HEALTHCARE REGULATOR HOSPITAL LIST – THE CHALLENGE • Public service mandates for 15 out of 16 Hirslanden hospitals: Klinik Im Park’s objection (Canton of Zurich) rejected; reapplication for 2016 • Extensive service mandates • Ongoing court cases (BE, SG) Hirslanden Analyst Presentation | February 2015 23 HEALTHCARE REGULATOR FURTHER REGULATORY CHALLENGES • Provisional DRG base rates • Outpatient tariff adjustment (shift of 200m Swiss francs from specialists to basic service providers) • Canton Vaud: Cantonal influence in acquisition of large medical equipment Hirslanden Analyst Presentation | February 2015 24 ENVIRONMENTAL CHALLENGES Outmigration of care Decreasing turnover per case Aging society From acute to chronical Regulatory environment Human resources Power of networks Increased transparency Limited market access Hirslanden Analyst Presentation | February 2015 25 OUTMIGRATION OF CARE AMBULATORY SURGERY VISITS UNITED STATES 1996 AND 2006 Ambulatory Inpatient 90 80 70 60 50 40 30 20 10 0 1996 2006 Data: CDC/NCHS, National Survey of Ambulatory Surgery, 2006 and National Hospital Discharge Survey. Hirslanden Analyst Presentation | February 2015 26 OUTMIGRATION OF CARE DEVELOPMENT IN OUTPATIENT BUSINESS IN SWITZERLAND Proportion of in- and outpatient cases in Swiss Hospitals 1996, 2004 and 2012 100 90 80 70 60 50 Outpatient 40 Inpatient 30 20 10 0 1996 2004 2012 Data: The Swiss Hospital Association H+, May 2014 Hirslanden Analyst Presentation | February 2015 27 BUSINESS OVERVIEW AND KEY STATISTICS Hirslanden Analyst Presentation | February 2015 28 THE SWISS HOSPITAL MARKET General Hospitals Employees (FTE) Beds 175 Hospitals 123'269 FTE 23'852 Acute beds 16% of privately held 32% of privately held 8% of total 35% of privately held 4% of total 6% of total 18% 82% Patient Care Days Cases Hirslanden Explanation 8.3m days 1.1m treated patients -Hirslanden's market share in % of private hospitals 31% of privately held 38% of privately held -Hirslanden's overall m/s 5% of total 7% of total 15% 18% Private Hospitals 85% 82% Public Hospitals Data: Swiss Federal Statistical Office (2012); Hirslanden. Hirslanden Analyst Presentation | February 2015 29 HIRSLANDEN OUR HOSPITALS Hirslanden Analyst Presentation | February 2015 30 HIRSLANDEN OUR AFFILIATED DOCTORS Hirslanden Analyst Presentation | February 2015 31 HIRSLANDEN OUR REFERRING DOCTORS Hirslanden Analyst Presentation | February 2015 32 OPERATIONAL OVERVIEW HOSPITALS BEDS 16 1 650 EMPLOYED VISITING EMPLOYEES SPECIALISTS SPECIALISTS 235 1 493 6 246 Hirslanden Analyst Presentation | February 2015 33 100 000 20000 40000 60000 80000 1 0001 0002 0003 0004 5 000 6 000 0007 GROWTH AT 0 Hirslanden 0 CAGR: CAGR: 2006 2004 CAGR: 4.4% CAGR: 3 607 29 016 3 628 56 719 2005 5.4% 2007 29 245 3 776 66 315 3 860 2006 Patients 08/09 34 062 4 107 67 019 4 166 2007 35 409 09/10 69 642 ( inpatient 4 288 08/09 4 343 FTE 35 178 73 448 10/11 09/10 HIRSLANDEN 4 419 34 553 cases 4 576 73 582 10/11 11/12 4 786 35 551 ) 4 871 77 643 11/12 12/13 37 808 5 016 80 588 Analyst Presentation | | 2015 Analyst February Presentation 5 065 12/13 38 898 13/14 82
Load more

Recommended publications
  • Press Release
    PRESS RELEASE Geneva, 9 September 2019 HIRSLANDEN CLINIQUE LA COLLINE JOINS LAVER CUP AS OFFICIAL MEDICAL PARTNER Hirslanden Clinique La Colline has been selected by the Laver Cup to become its official medical partner in Geneva, September 20-22, 2019. The Laver Cup today announced its official medical partnership with Hirslanden Clinique La Colline, who’s recently inaugurated Sports Medicine Center has been recognized by Swiss Olympic as Sport Medical Center and professional osteopathy services in the tennis field. Hirslanden Clinique La Colline will be working with Laver Cup and ATP Physiotherapists to provide dedicated treatment and massage therapy services during the tournament. “We are delighted to become the official medical partner of the Laver Cup in Geneva. With our combined expertise in sports medicine, orthopedics and osteopathy, our goal is to enable Team Europe and Team World to showcase the best of their abilities in Geneva. Performance is a matter of preparation and discipline”, says Gilles Rufenacht, Director of Hirslanden Clinique La Colline in Geneva. “We look forward to working with the professional team at Hirslanden at the Laver Cup in Geneva. Their experienced practitioners will be a key asset for all the players, and will ensure both teams have access to the services they need to prepare for what promises to be an incredible weekend of tennis action,” Laver Cup CEO Steve Zacks said. “ Information: Hirslanden Clinique La Colline Laver Cup Magali Dauwalder Prue Ryan Head of Communications Head of Public Relations T +41 79 107 56 76 +61 419 308 369 [email protected] [email protected] www.hirslanden.ch Hirslanden Private Hospital Group As of 31 March 2019, the Hirslanden Private Hospital Group consists of 18 hospitals in 11 cantons, many of which have an integrated outpatient surgery centre and emergency department.
    [Show full text]
  • COVID-19 - ESSKA Guidelines and Recommendations for Resuming Elective Surgery Caroline Mouton, Michael Hirschmann, Matthieu Ollivier, Romain Seil, Jacques Menetrey
    COVID-19 - ESSKA guidelines and recommendations for resuming elective surgery Caroline Mouton, Michael Hirschmann, Matthieu Ollivier, Romain Seil, Jacques Menetrey To cite this version: Caroline Mouton, Michael Hirschmann, Matthieu Ollivier, Romain Seil, Jacques Menetrey. COVID- 19 - ESSKA guidelines and recommendations for resuming elective surgery. Journal of Experimental Orthopaedics, Springer Verlag, 2020, 7 (1), pp.28. 10.1186/s40634-020-00248-4. hal-03175930 HAL Id: hal-03175930 https://hal.archives-ouvertes.fr/hal-03175930 Submitted on 22 Mar 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License Mouton et al. Journal of Experimental Orthopaedics (2020) 7:28 Journal of https://doi.org/10.1186/s40634-020-00248-4 Experimental Orthopaedics REVIEW Open Access COVID-19 - ESSKA guidelines and recommendations for resuming elective surgery Caroline Mouton1,2, Michael T. Hirschmann3, Matthieu Ollivier4, Romain Seil1,2 and Jacques Menetrey5,6* Abstract The roadmap to elective surgery resumption after this COVID-19 pandemic should be progressive and cautious. The aim of this paper was to give recommendations and guidelines for resuming elective orthopedic surgery in the safest environment possible.
    [Show full text]
  • Prospectus Relating to Mediclinic Combination
    NOTICE IMPORTANT: You must read the following before continuing. The following applies to the document following this notice, whether received by email or otherwise received as a result of electronic communication. You are advised to read this disclaimer carefully before reading, accessing or making any other use of the document. In accessing the document, you agree to be bound by the following terms and conditions, including any modifications to them, each time you receive any information as a result of such access. NOTHING IN THIS ELECTRONIC TRANSMISSION CONSTITUTES AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. THE FOLLOWING DOCUMENT MAY NOT BE FORWARDED OR DISTRIBUTED TO ANY OTHER PERSON AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER. ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THIS DOCUMENT IN WHOLE OR IN PART IS UNAUTHORISED. FAILURE TO COMPLY WITH THIS DIRECTIVE MAY RESULT IN A VIOLATION OF THE U.S. SECURITIES ACT OF 1933 (THE ‘‘SECURITIES ACT’’) OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS. This document does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or any other jurisdiction where such offer or sale would be unlawful. The shares that may be received in the business combination described in the following document (the ‘‘Combination’’) have not been, and will not be, registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction in the United States, and may only be offered or sold in reliance on the exemption from the registration requirements of the Securities Act provided by Rule 802 under the Securities Act.
    [Show full text]
  • Right Colon Cancer : Left Behind ?
    Article Right colon cancer : left behind ? GERVAZ, Pascal, BOUCHARDY MAGNIN, Christine, USEL, Massimo Reference GERVAZ, Pascal, BOUCHARDY MAGNIN, Christine, USEL, Massimo. Right colon cancer : left behind ? British Journal of Surgery, 2013, vol. 100, no. s5, p. 8 DOI : 10.1002/bjs.9154 Available at: http://archive-ouverte.unige.ch/unige:90372 Disclaimer: layout of this document may differ from the published version. 1 / 1 SSS abstracts Swiss Society of Surgery The following abstracts will be presented at the 100th Annual Congress of the Swiss Society of Surgery, held in Berne 12–14 June 2013. Visceral of the operation according to a standardised protocol. The patient, the surgeon and the outcome assessors were blinded. Clinical follow-up investigations were Effect of intra-operative infiltration with local anesthesia on the performed after one day, 2 weeks, 1, 3, and 12 months postoperatively. Three development of chronic pain after inguinal hernia repair. A randomized interim analyses with data monitoring committee meetings were performed to controlled triple-blinded trial check whether stopping criteria were met or the sample size had to be adapted. A. Kurmann1,2,H.Fischer3, N. Wippich3, S. Dell-Kuster4,5, The study was stopped after the third interim analysis for futility reasons R. Rosenthal5,J.Metzger3, P. Honigmann3,6 because it was unlikely that significance could be reached within an adequate sample size and time. Chronic postoperative pain was estimated by means of 1 Department of Visceral Surgery, Cantonal Hospital Luzern, Luzern, Switzerland, a Visual Analogue Scale (VAS) and defined as any pain (VAS > 0) 3 months 2 Department of Visceral Surgery and Medicine, University Hospital Bern, Bern, postoperatively.
    [Show full text]
  • Medical Specialty Title Firstname Name Street Zip Town Region
    Languages English Updat Medical Specialty Title Firstname Name Street Zip Town Region Hospital/Organization Phone Website E-mail spoken Language ed English, Alternative Medicine - Shiatsu Mrs. Susan Vogt Freie Strasse 97 4051 Basel BASEL 061 272 58 78 [email protected] Extensive 2019 German English, German, Chiropractic Dr. Peter Rufener St. Alban-Anlage 27 4052 Basel BASEL 061 271 76 62 [email protected] Extensive 2019 French, Spanish English, Dental Medicine Dr. Daniel Hänggi Birsigstrasse 105 4054 Basel BASEL Private practice 061 281 33 66 www.praxishaenggi.ch [email protected] German, Extensive 2019 French English, Extensive German, (Dentist), Swedish, Limited Dental Medicine Dr. Ines Miolin Oberwilerstrasse 133 4054 Basel BASEL Private practice 061 281 15 16 www.miolin.ch [email protected] 2019 Italian, (Assistance French, + Spanish Telephone) English, German (dental assistants Dental Medicine Dr. Donna Hänggi Birsigstrasse 105 4054 Basel BASEL Praxis D. Hänggi 061 281 33 66 www.praxishaenggi.ch [email protected] Extensive 2019 fluent in Spanish, Italian and English,French) German, Dental French, Dr. Nenad Antic Holbeinstrasse 52 4051 Basel BASEL 061 283 80 20 www.drantic.ch [email protected] Extensive 2019 Medicine/Implantology/Periodontology Italian, Spanish, Romanian English, German, Ear, Nose & Throat Dr. med. Annemarie Haag Jordan Schifflaende 2 4051 Basel BASEL 061 262 02 66 www.basel-hno.ch [email protected] French, Extensive 2019 Spanish, Italian English, General Practice / Internal Medicine / Dr. med. Gideon Nagel Burgfelderstrasse 200 4055 Basel BASEL 061 322 10 22 www.baslerdoctor.com [email protected] Hebrew, Extensive 2019 Geriatrics German English, www.bethesda.ch German, Gynecology and Obstetrics Dr.
    [Show full text]
  • 2021 Clinical Services Report Contents
    TOGETHER WE CARE 2021 CLINICAL SERVICES REPORT CONTENTS MEDICLINIC’S CORE PURPOSE IS TO ENHANCE THE QUALITY OF LIFE 25 2 COVID-19 overview Introduction 8 About Mediclinic 8 At a glance 9 Committed to clients 10 Highlights Better ways to connect Mediclinic’s healthcare Employees keep clients at the heart of all landscape Mediclinic does. That is the commitment 11 Unique but united behind putting Patients First. 20 Value equation index 34 Better ways to connect 25 Patient experience 34 Better ways to unlock value Better ways to care 36 Clinical performance Klinik Hirslanden, Switzerland 44 Clinical outcomes Better ways to unlock value The Group is dedicated to partnering with 58 Facility focus all its stakeholders and forging long-term relationships. 59 Partnerships 36 61 Assurance 63 Clinical ethics summary 65 Glossary of terms 67 Contact details Better ways to care Superior clinical performance is essential to achieve Mediclinic’s purpose of enhancing the quality of life. ABOUT THIS REPORT Mediclinic International plc (‘Mediclinic’ or the ‘Company’) is proud to publish a Clinical Services Report annually as part of a suite of reports in respect of both the 2020 calendar year and 2021 financial year. The reporting suite listed below is available on the Group’s website. 2021 Annual Report and Financial Statements 2021 Clinical Services Report 2021 Sustainable Development Report 2021 Modern Slavery Statement 2021 Notice of Annual General Meeting SCOPE The goal of this Report is to provide Mediclinic stakeholders with an overview of the most important clinical performance characteristics across its divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates (‘UAE’) (collectively, the ‘Group’) for the 2020 calendar year, unless stated otherwise.
    [Show full text]
  • US Embassy Bern
    Hospital/ Languages English Medical Specialty Title Firstname Name Street Zip Town Region Phone Website E-mail Updated Organization spoken Language Alternative Medicine - English, Mrs. Susan Vogt Freie Strasse 97 4051 Basel BASEL 061 272 58 78 [email protected] Extensive 2020 Shiatsu German English, German, Chiropractic Dr. Peter Rufener St. Alban-Anlage 27 4052 Basel BASEL 061 271 76 62 [email protected] Extensive 2020 French, Spanish English, Dental Medicine Dr. Daniel Hänggi Birsigstrasse 105 4054 Basel BASEL Private practice 061 281 33 66 www.praxishaenggi.ch [email protected] German, Extensive 2020 French English, Extensive German, (Dentist), Swedish, Dental Medicine Dr. Ines Miolin Oberwilerstrasse 133 4054 Basel BASEL Private practice 061 281 15 16 www.miolin.ch [email protected] Limited 2020 Italian, (Assistance + French, Telephone) Spanish English, German (dental assistants Dental Medicine Dr. Donna Hänggi Birsigstrasse 105 4054 Basel BASEL Praxis D. Hänggi 061 281 33 66 www.praxishaenggi.ch [email protected] Extensive 2020 fluent in Spanish, Italian and French) English, German, Dental Medicine/ French, Implantology/ Dr. Nenad Antic Holbeinstrasse 52 4051 Basel BASEL 061 283 80 20 www.drantic.ch [email protected] Extensive 2020 Italian, Periodontology Spanish, Romanian English, German, Ear, Nose & Throat Dr. med. Annemarie Haag Jordan Schifflaende 2 4051 Basel BASEL 061 262 02 66 www.basel-hno.ch [email protected] French, Extensive 2020 Spanish, Italian General Practice / English, Internal Medicine / Dr. med. Gideon Nagel Burgfelderstrasse 200 4055 Basel BASEL 061 322 10 22 www.baslerdoctor.com [email protected] Hebrew, Extensive 2020 Geriatrics German English, Gynecology and 4102 Binningen www.bethesda.ch Dr.
    [Show full text]
  • CLINICS and HEALTH in GENEVA Geneva Offers a Large Selection of Clinics, Each Characterised by Its State-Of-The-Art Facilities
    CLINICS AND HEALTH IN GENEVA Geneva offers a large selection of clinics, each characterised by its state-of-the-art facilities. They offer care and personalised attention as well as a hotel and culinary service of five-star quality. Groupe La Tour Avenue J.D. Maillard 3 - 1217 Meyrin Web: http://www.la-tour.ch/fr/ Telephone: +41 22 719 61 11 Let's build tomorrow's healthcare together. La Tour is the largest private hospital group in the Canton of Geneva and comprises the Hôpital de La Tour, the Clinique de Carouge and the Centre Médical de Meyrin. The Hôpital de La Tour is the only private acute care facility in French-speaking Switzerland to offer a 24/7 emergency service, a ten-bed intensive care unit, a renal dialysis centre and a level IIA neonatal unit. A pioneer in embracing numerous innovations, and a hub for over 60 medical specialisations, each year the Groupe La Tour welcomes 7,000 inpatients and 300,000 outpatients including 40,000 emergencies, as well as performing 5,800 operations and training 40 doctors across seven medical disciplines. It employs 950staff and has 350 registered doctors. To guarantee integrated and personalised care to its patients and their families, its activities are organised into six healthcare pathways: - Orthopaedics and sports medicine - Oncology - Metabolism and obesity - Internal medicine - Cardiology - Woman and child The La Tour group's facilities are recognised on the Canton of Geneva’s hospital list and are also mandated to accept patients without additional private health insurance in certain specific cases. Outpatient services are available to all those with basic national health insurance (LAMal and LAA).
    [Show full text]
  • 2018 Capital Markets Day Presentation
    2018 CAPITAL MARKETS DAY 28 JUNE 2018 ZURICH, SWITZERLAND WELCOME DR RONNIE VAN DER MERWE CEO MEDICLINIC INTERNATIONAL MEDICLINIC DISCLAIMER This presentation contains certain forward-looking statements relating to the financial condition, the regulatory environment in which we operate, results of operations and businesses of Mediclinic and the Group, including certain plans and objectives of the Group. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Mediclinic to market risks and statements expressing management’s expectations, beliefs, estimates, forecasts, projections and assumptions, including as to future potential cost savings, synergies, earnings, cash flow, production and prospects. These forward-looking statements are identified by their use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “goals”, “intend”, “may”, “objectives”, “outlook”, “plan”, “probably”, “project”, “risks”, “seek”, “should”, “target”, “will” and similar terms and phrases. Slide 3 2018 CAPITAL MARKETS DAY AGENDA 1 Introduction and Group Overview
    [Show full text]
  • Acquisition of Clinique La Colline
    MDC - MEDICLINIC INTERNATIONAL LIMITED - Acquisition of Clinique La Colline June 25, 2014 Acquisition of Clinique La Colline Mediclinic International Limited (Incorporated in the Republic of South Africa) (Registration number 1983/010725/06) JSE share code: MDC ISIN: ZAE000074142 ("Mediclinic" or "the Company") ACQUISITION OF CLINIQUE LA COLLINE Shareholders are referred to the announcement released on SENS on 11 June 2014 in which the Company set out its intentions to raise equity capital to fund various acquisitions and investment opportunities, one of which is an acute care multi-disciplinary hospital in Switzerland. Mediclinic is pleased to announce that all conditions precedent to the transaction have been fulfilled and subsequently its Swiss business, Hirslanden, has acquired a 100% interest in the operating business of Clinique La Colline ("La Colline") in Geneva, Switzerland (hereinafter referred to as "the Transaction"). Overview of La Colline and transaction rationale La Colline is a multi-disciplinary medical and surgical private hospital with 95 beds (including inpatient, outpatient and specialty beds) and six operating theatres equipped for general, endoscopic, and navigation-assisted surgery. La Colline has a significant market share in orthopaedic treatments performed in Geneva. Other treatments offered at La Colline include internal medicine, visceral surgery, neurology, ophthalmology, general surgery, urology, plastic surgery, and gynaecology. The Transaction significantly strengthens Hirslanden's position in Western Switzerland, through providing a footprint in Geneva, and is in line with the Company's strategy to increase capacity in attractive markets with strong fundamentals. Purchase consideration The total enterprise value paid for La Colline will be c.CHF130m representing a LTM EV/EBITDA multiple of 8.7x.
    [Show full text]
  • 2019 Annual Report Contents
    MEDICLINIC INTERNATIONAL PLC MEDICLINIC INTERNATIONAL | ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2019 ANNUAL 2019 ANNUAL REPORT CONTENTS 4 At a glance GOVERNANCE AND REMUNERATION 103 Chairman’s Introduction STRATEGIC REPORT 104 Board of Directors Business overview 110 Group Executive Committee 10 Performance summary 114 Corporate Governance Statement 12 Chairman’s Statement 136 Audit and Risk Committee Report 16 Business model 150 Clinical Performance and Sustainability 18 Our strategy, goals and progress Committee Report 22 Investment case 154 Nomination Committee Report 23 Five-year summary 159 Directors’ Remuneration Report Performance and future outlook 179 Statement of Directors’ Responsibilities 24 Chief Executive Officer’s Review 29 Financial Review FINANCIAL STATEMENTS 40 Value added statement 182 Group Financial Statements 41 Clinical services overview 280 Company Financial Statements Risk management ADDITIONAL INFORMATION 55 Risk management, principal risks and uncertainties 296 Shareholder information 60 Viability statement 300 Company information Divisional reviews 302 Forward-looking statements 62 Divisional Review – Switzerland 303 Glossary 67 Divisional Review – Southern Africa 71 Divisional Review – UAE Non-financial performance 76 Sustainable development overview 100 Non-financial information statement OVERVIEW ADAPTING LOSS OF MEDICLINIC TO THE CHANGING GLOBAL £151M* HEALTHCARE impacted by non-cash ENVIRONMENT Hirslanden and Spire impairment charges and is a priority with focus other exceptional items throughout the
    [Show full text]
  • Mediclinic International Annual Report 2020
    ENHANCING THE QUALITY OF LIFE 2020 ANNUAL REPORT STRATEGIC REPORT Introduction 4 Section 172 statement 6 Non-financial information statement 7 Report profile 8 Performance summary 10 At a glance Business overview MEDICLINIC’S 12 Market overview 14 Business model CORE PURPOSE 16 Investment case 18 Value added statement IS TO ENHANCE 19 Five-year summary Performance and outlook THE QUALITY 20 Chair’s Review 28 Group Chief Executive Officer’s Report 36 Strategy, goals and progress OF LIFE 44 Continuum of care 46 Stakeholders summary 50 Clinical services overview 62 Sustainable development overview 78 Group Chief Financial Officer’s Report 92 Divisional Report – Hirslanden 100 Divisional Report – Mediclinic Southern Africa 106 Divisional Report – Mediclinic Middle East Risk management 114 Viability statement 116 Emergency preparedness summary 119 Risk management, principal risks and uncertainties GOVERNANCE AND REMUNERATION REPORT 128 Chair’s Introduction 130 Board of Directors 136 Group Executive Committee 138 Corporate Governance Statement 170 Audit and Risk Committee Report 184 Clinical Performance and Sustainability Committee Report 188 Nomination Committee Report 194 Remuneration Committee Report 221 Statement of Directors’ Responsibilities FINANCIAL STATEMENTS 224 Group financial statements 330 Company financial statements ADDITIONAL INFORMATION 348 Shareholder information 351 Company information 352 Forward-looking statements 353 Glossary of terms To find out more visit: www.mediclinic.com CONTINUUM OF CARE Expansion across the continuum of care will widen the Group’s service focus, improve accessibility and create the opportunity to form a lasting relationship with clients. 44 50 CLINICAL QUALITY More than 75 clinical indicators are measured monthly across the divisions to identify trends and opportunities for improvement.
    [Show full text]